Federal Appellate Court: Pay-for-Delay is “prima facie evidence of an unreasonable restraint of trade.”
On Monday, July 16, 2012, the Court of Appeals for the Third Circuit ruled that pay-for-delay agreements between branded pharmaceutical companies and generic manufacturers are prima facie evidence of anticompetitive behavior. Continue Reading